Free Trial
OTCMKTS:FSNUY

Fresenius SE & Co. 5/7/2025 Earnings Report

Fresenius SE & Co. logo
$12.09 -0.14 (-1.14%)
As of 03:51 PM Eastern

Fresenius SE & Co. EPS Results

Actual EPS
$0.23
Consensus EPS
$0.22
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Fresenius SE & Co. Revenue Results

Actual Revenue
$5.92 billion
Expected Revenue
$5.41 billion
Beat/Miss
Beat by +$513.12 million
YoY Revenue Growth
N/A

Fresenius SE & Co. Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Fresenius SE & Co.'s next earnings date is estimated for Wednesday, July 30, 2025, based on past reporting schedules.

Conference Call Resources

Fresenius SE & Co. Earnings Headlines

Fresenius SE & Co. KGaA (FSNUY) - Yahoo Finance
Ex-Hedge Fund Manager Uncovers $100 Trillion Land Shift
Trump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to unlock federal lands, oil reserves, and buried minerals... all for profit. Trump's team is already executing the orders... and Wall Street legend Whitney Tilson is stepping forward to show you how to position before the deadline.
FSNUY Fresenius SE & Co. KGaA - Seeking Alpha
Fresenius: Healthy Portfolio Add
See More Fresenius SE & Co. Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fresenius SE & Co.? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fresenius SE & Co. and other key companies, straight to your email.

About Fresenius SE & Co.

Fresenius SE & Co. (OTCMKTS:FSNUY) KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

View Fresenius SE & Co. Profile

More Earnings Resources from MarketBeat